This study is looking at whether adding a special liquid diet, called partial enteral nutrition (PEN), to standard advanced medications can help people with active Crohn's disease. Participants will consume Kate Farms Peptide 1.5 for about 60% of their daily calories, along with following the Crohn's Disease Exclusion Diet. You can join if you are starting a new advanced Crohn's therapy (like anti-TNF or anti-IL23 medications) and are between 18 and 80 years old. The main goal is to see how many people achieve steroid-free remission after 8 weeks. This study is currently recruiting 80 participants across 15 sites in the United States.

Study design

This is an open-label study, meaning both you and the study team will know which treatment you are receiving. It is not randomized, so you will choose whether to include PEN or not. The study plans to enroll 80 participants.

What's involved

You would consume Kate Farms Peptide 1.5 for approximately 60% of your calories while following the Crohn's Disease Exclusion Diet. The primary endpoint is measured after 8 weeks of pharmacologic therapy.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoint is measured 8 weeks after starting pharmacologic therapy.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.